Pulmongene Appoints Hunter C. Gillies, M.B.Ch.B, as Chief Medical Officer to Lead Global Clinical Development in Fibrotic and Pulmonary Diseases 2026-07-08 Pulmongene Appoints Hunter C. Gillies, M.B.Ch.B, as Chief Medical Officer to Lead Global Clinical Development in Fibrotic and Pulmonary Diseases Read More »
Pulmongene‘s PMG1015 Granted FDA Fast Track Designation for Treatment of Idiopathic Pulmonary Fibrosis (IPF) 2026-03-25 Pulmongene‘s PMG1015 Granted FDA Fast Track Designation for Treatment of Idiopathic Pulmonary Fibrosis (IPF) Read More »
Pulmongene Announces FDA Clearance to initiate 52-Week Phase IIb Global MRCT for PMG 1015, a First-in-Class Therapeutic Antibody for IPF 2026-01-19 Pulmongene Announces FDA Clearance to initiate 52-Week Phase IIb Global MRCT for PMG 1015, a First-in-Class Therapeutic Antibody for IPF Read More »
Pulmongene announces to present PMG1015 Phase 1b Clinical Trial Results as a Late-Breaking Abstract at European Respiratory Society Congress (ERS) 2025 2025-09-02 Pulmongene announces to present PMG1015 Phase 1b Clinical Trial Results as a Late-Breaking Abstract at European Respiratory Society Congress (ERS) 2025 Read More »
Pulmongene Announces First Patient Dosed in Phase 1b Clinical Trial Evaluating PMG1015 in Idiopathic Pulmonary Fibrosis Patients 2023-07-05 Pulmongene Announces First Patient Dosed in Phase 1b Clinical Trial Evaluating PMG1015 in Idiopathic Pulmonary Fibrosis Patients Read More »
FDA Grants Orphan Drug Designation to Pulmongene’s PMG1015 for treatment of Idiopathic Pulmonary Fibrosis (IPF) 2023-02-17 FDA Grants Orphan Drug Designation to Pulmongene’s PMG1015 for treatment of Idiopathic Pulmonary Fibrosis (IPF) Read More »
